
    
      Despite allogeneic HSCT is the only curative therapy for AML, some patients can not receive
      transplantation due to intolerance of transplant-related toxicity or unwillingness of HSCT.
      For these patients, microtransplantation seems an optional therapy. However, the efficacy
      still remain unclear.
    
  